Rafael Holdings Inc (RFL) Stock Price, Quote & News

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services

Sector: Real Estate

Phone: 212 658 1450

Website: www.rafaelholdings.com

Address:

520 Broad Street, Newark, United States

CaseOfTheYips1 May. 8 at 5:24 PM

$FLNA SAVA is dead. Cyclo is now officially a better asset! It was only a matter of time.. come join $RFL before our readout this summer!!

1 · Reply

CaseOfTheYips1 May. 8 at 5:21 PM

$RFL been waiting for this day… Our sp has surpassed sava! Congratulations on us being better than that dumpster fire.

0 · Reply

CaseOfTheYips1 May. 8 at 12:27 AM

$RFL One of the things I would like to see in the next six weeks is advertising for production and commercialization positions. Maybe a few sales people. That would be a good indicator that they have high confidence. If anybody can monitor their employment page, that would be helpful.

1 · Reply

Biotechnicity May. 7 at 6:04 PM

$RFL According to StockTwits own summation, Zevra is reporting that MIPLYFFA is causing “hypersensitivity reactions” (a known issue in previous studies regarding breathing through the nose). The stock is down 6% and the door to Cyclo opens wider while the jump height on P-3 success expands higher.

0 · Reply

st0ney May. 7 at 5:10 PM

$RFL I’m down 95% in this and won’t ever recovery my money

1 · Reply

Aye_Sir May. 7 at 12:02 PM

$RFL Is Mo still here?

1 · Reply

CaseOfTheYips1 May. 6 at 7:31 PM

$RFL would love to see $1.45 hit and stick… been on life support too long..

0 · Reply

FullTrust May. 6 at 3:34 PM

$AKBA $RFL $BIYA $SDOT Take a deeper look if you’ve been following along akebians Sdot taking former lows, great in future if it follows akba playbook off .241 low Biya taking lower range, hopefully akba can take some higher ranges from biya John hopefully has a never looking back generational catalyst for us

0 · Reply

FullTrust May. 6 at 3:24 PM

$AKBA $RFL 1.52 super filler

0 · Reply

Doozio May. 6 at 12:37 AM

$RFL ONTO 🐒🍌🧠⏰♾️?

0 · Reply

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

Mar 16, 2026, 4:01 PM EDT - 7 weeks ago

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Dec 11, 2025, 4:01 PM EST - 5 months ago

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Oct 29, 2025, 4:24 PM EDT - 6 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 28, 2025, 4:01 PM EDT - 6 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Sep 16, 2025, 8:00 AM EDT - 8 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Aug 27, 2025, 8:00 AM EDT - 9 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

2025-06-18T11:10:50.000Z - 11 months ago

Rafael announces continuation of Phase 3 TransportNPC study following DMC review

2025-06-11T11:05:50.000Z - 11 months ago

Rafael Holdings reports Q3 EPS (19c) vs ($1.36) last year

Jun 11, 2025, 7:00 AM EDT - 11 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 4, 2025, 4:01 PM EDT - 1 year ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

May 20, 2025, 4:01 PM EDT - 1 year ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

2025-05-05T11:21:47.000Z - 1 year ago

Rafael announces revised subscription rights in connection with offering

May 5, 2025, 7:00 AM EDT - 1 year ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 1 year ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Mar 26, 2025, 6:50 AM EDT - 1 year ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 13, 2025, 5:50 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

2024-12-11T12:06:09.000Z - 1 year ago

Rafael Holdings reports Q1 EPS (37c) vs (15c) last year

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

2024-08-22T10:52:19.000Z - 1 year ago

Rafael Holdings, Cyclo Therapeutics enter merger agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Jun 14, 2024, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Aug 2, 2023, 8:16 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Jun 13, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

2023-04-04T12:22:42.000Z - 3 years ago

Rafael Holdings announces up to $5M share repurchase program

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

2022-12-13T12:21:32.000Z - 3 years ago

Rafael Holdings reports Q1 EPS (22c) vs. ($5.88) last year

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Aug 23, 2022, 7:43 AM EDT - 4 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Jul 6, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jun 16, 2022, 2:14 PM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 14, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 1, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

May 24, 2022, 11:04 AM EDT - 4 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

CaseOfTheYips1 May. 8 at 5:24 PM

$FLNA SAVA is dead. Cyclo is now officially a better asset! It was only a matter of time.. come join $RFL before our readout this summer!!

1 · Reply

CaseOfTheYips1 May. 8 at 5:21 PM

$RFL been waiting for this day… Our sp has surpassed sava! Congratulations on us being better than that dumpster fire.

0 · Reply

CaseOfTheYips1 May. 8 at 12:27 AM

1 · Reply

Biotechnicity May. 7 at 6:04 PM

0 · Reply

st0ney May. 7 at 5:10 PM

$RFL I’m down 95% in this and won’t ever recovery my money

1 · Reply

Aye_Sir May. 7 at 12:02 PM

$RFL Is Mo still here?

1 · Reply

CaseOfTheYips1 May. 6 at 7:31 PM

$RFL would love to see $1.45 hit and stick… been on life support too long..

0 · Reply

FullTrust May. 6 at 3:34 PM

0 · Reply

FullTrust May. 6 at 3:24 PM

$AKBA $RFL 1.52 super filler

0 · Reply

Doozio May. 6 at 12:37 AM

$RFL ONTO 🐒🍌🧠⏰♾️?

0 · Reply

Biotechnicity May. 5 at 5:18 PM

$RFL 🤣 brings added meaning to the expression: you got fined. Scott or Randy it’s always a dandy.

1 · Reply

Biotechnicity May. 5 at 1:18 PM

$RFL all of these companies soaking retail while swimming in place until the collapse. Just pathetic!

0 · Reply

sg44 May. 4 at 10:16 PM

$RFL apart from trial results DAY another very important date for our little baby stock is October 30. If the market cap is high enough we're IN and all institutions will be forced to BUY. Because of this I don't expect readout soon maybe later in September.

1 · Reply

Biotechnicity May. 4 at 8:06 PM

$RFL man these p-3 trials are expensive to run! I had projected about $100M but Cyclo may have exceeded that. Anyone know the actual numbers?

0 · Reply

History101 May. 1 at 4:23 AM

$RFL 1,741 watching 4/30/2026

0 · Reply

Biotechnicity Apr. 30 at 7:56 PM

$RFL 7-8x the normal volume.

0 · Reply

Moksi Apr. 30 at 6:08 PM

$RFL this Will blow

0 · Reply

Fashtrades Apr. 30 at 3:44 PM

$RFL .. One month and half away !! .. Very

1 · Reply

solistocks Apr. 30 at 3:05 PM

$RFL what's expectations. Middle or end of June for the readout? What happens there and what happens next? Lot of us been here a long time. No word on Alzheimer's no word on her2 cancer??? Lots of excitement ahead.

2 · Reply

ButterCall Apr. 30 at 2:59 PM

$RFL The longer the base, the higher in space

0 · Reply

Rat_Bastard2 Apr. 28 at 6:29 PM

$RFL Oh it scares the hell out of me, too, but I’m gonna HOLD! Haha that’s some funny shit right there. Granddaughter_Bastard thought this was the end of all things. RFL is indeed a roller coaster ride!

1 · Reply

CaseOfTheYips1 Apr. 28 at 3:46 PM

$RFL 6 weeks…

1 · Reply

Market Cap	66.06M
Revenue (ttm)	920,000.00
Net Income (ttm)	-30.52M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,317.39%
Debt to Equity Ratio	0.01

Volume	58,300
Avg Vol	85,352
Day's Range	N/A - N/A
Shares Out	52.01M
Stochastic %K	43%
Beta	0.50
Analysts	Strong Buy
Price Target	N/A